![Cognitive data in the Parkinson's Progression Markers Initiative: Comparison of normative data approaches - MDS Abstracts Cognitive data in the Parkinson's Progression Markers Initiative: Comparison of normative data approaches - MDS Abstracts](https://www.mdsabstracts.org/wp-content/uploads/2017/05/0037-001133_001.jpg)
Cognitive data in the Parkinson's Progression Markers Initiative: Comparison of normative data approaches - MDS Abstracts
![Frontiers | Trajectory Analysis of Orthostatic Hypotension in Parkinson's Disease: Results From Parkinson's Progression Markers Initiative Cohort Frontiers | Trajectory Analysis of Orthostatic Hypotension in Parkinson's Disease: Results From Parkinson's Progression Markers Initiative Cohort](https://www.frontiersin.org/files/Articles/762759/fnagi-13-762759-HTML/image_m/fnagi-13-762759-g001.jpg)
Frontiers | Trajectory Analysis of Orthostatic Hypotension in Parkinson's Disease: Results From Parkinson's Progression Markers Initiative Cohort
![Identification and prediction of Parkinson's disease subtypes and progression using machine learning in two cohorts | npj Parkinson's Disease Identification and prediction of Parkinson's disease subtypes and progression using machine learning in two cohorts | npj Parkinson's Disease](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41531-022-00439-z/MediaObjects/41531_2022_439_Fig1_HTML.png)
Identification and prediction of Parkinson's disease subtypes and progression using machine learning in two cohorts | npj Parkinson's Disease
![Assessment of heterogeneity and disease onset in the Parkinson's Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study | medRxiv Assessment of heterogeneity and disease onset in the Parkinson's Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study | medRxiv](https://www.medrxiv.org/content/medrxiv/early/2023/03/01/2023.02.27.23286156/F1.large.jpg)
Assessment of heterogeneity and disease onset in the Parkinson's Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study | medRxiv
![Cleveland Clinic Lou Ruvo Center for Brain Health Joins Michael J. Fox Foundation's Expansion of Parkinson's Progression Markers Initiative (PPMI) – Cleveland Clinic Newsroom Cleveland Clinic Lou Ruvo Center for Brain Health Joins Michael J. Fox Foundation's Expansion of Parkinson's Progression Markers Initiative (PPMI) – Cleveland Clinic Newsroom](https://newsroom.clevelandclinic.org/wp-content/uploads/sites/4/2023/04/Zoltan-Mari-MD-lab-coat-PS5_3405-2-2.jpg)
Cleveland Clinic Lou Ruvo Center for Brain Health Joins Michael J. Fox Foundation's Expansion of Parkinson's Progression Markers Initiative (PPMI) – Cleveland Clinic Newsroom
![Sample size estimation for clinical trials in de novo Parkinson's disease (PD): Results from the Parkinson's Progression Markers Initiative (PPMI) Study - MDS Abstracts Sample size estimation for clinical trials in de novo Parkinson's disease (PD): Results from the Parkinson's Progression Markers Initiative (PPMI) Study - MDS Abstracts](https://www.mdsabstracts.org/wp-content/uploads/2017/05/0037-002207_001.png)
Sample size estimation for clinical trials in de novo Parkinson's disease (PD): Results from the Parkinson's Progression Markers Initiative (PPMI) Study - MDS Abstracts
Over the last 10 years, volunteers in the Parkinson's Progression Markers Initiative (PPMI) have helped expand our understandi
![michaeljfox.org on Twitter: "(2/2) Our landmark Parkinson's Progression Markers Initiative study is learning more about the connection between sleep and brain disease. Whether you or your partner experience sleep issues, you both michaeljfox.org on Twitter: "(2/2) Our landmark Parkinson's Progression Markers Initiative study is learning more about the connection between sleep and brain disease. Whether you or your partner experience sleep issues, you both](https://pbs.twimg.com/media/FM8m7K4XsAIudyl.jpg:large)
michaeljfox.org on Twitter: "(2/2) Our landmark Parkinson's Progression Markers Initiative study is learning more about the connection between sleep and brain disease. Whether you or your partner experience sleep issues, you both
![Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study - The Lancet Neurology Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study - The Lancet Neurology](https://www.thelancet.com/cms/attachment/0dda957a-5bbe-4ce4-9f7e-d6d277883585/gr1_lrg.jpg)
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study - The Lancet Neurology
![Evaluation of the PREDIGT score's performance in identifying newly diagnosed Parkinson's patients without motor examination | npj Parkinson's Disease Evaluation of the PREDIGT score's performance in identifying newly diagnosed Parkinson's patients without motor examination | npj Parkinson's Disease](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41531-022-00360-5/MediaObjects/41531_2022_360_Fig1_HTML.png)